Evotec SE today announced that new high-throughput screening (“HTS”) facilities at the Company’s headquarters in Hamburg, as well as additional equipment for investigating the safety and efficacy of new therapeutic candidates have been put into operation. Hamburg’s Senator for Economic Affairs, Dr Melanie Leonhard, visited Evotec’s Manfred Eigen Campus to see how the expanded HTS facilities in combination with technologies of the future will be used to accelerate drug discovery. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-accelerating-drug-discovery-with-screening-technologies-of-the-future-through-erdfreact-eu-grant-6296
Publication of Sustainability Report 2022
Evotec has published its Sustainability Report 2022. In reference to the GRI standards and for the first time partially audited, it is a testament to our progress made in shaping a resilient and sustainable business together with our partners, designed to cope with and to seize future opportunities from a variety of challenges today. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/publication-of-sustainability-report-2022-6294
Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023
Evotec SE today published its Annual Report for the fiscal year 2022, as well as the qualitative Quarterly Statement for the first quarter of 2023. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-publishes-annual-report-2022-and-quarterly-statement-for-q1-2023-6293
Just – Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing
Evotec SE and Sandoz AG, a division of Novartis (NASDAQ: NVS) today announced that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., launched a multi-year, long-term tech partnership with Sandoz for the immediate development and subsequent manufacturing of multiple biosimilars. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/just—evotec-biologics-launches-tech-partnership-for-biosimilars-development-and-commercial-manufacturing-6290
Evotec SE: Statement regarding unscheduled change in Qontigo indices
Evotec has been informed that Qontigo, the index operator of Deutsche Boerse, has decided to remove Evotec from MDAX and TecDAX effective 09 May. The reason for the unexpected index change was explained with the delay in the publication of the Company’s audited Annual Financial Report. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-statement-regarding-unscheduled-change-in-qontigo-indices-6286
Cyprotex US celebrates Grand Opening of new facility in Framingham, MA
Evotec SE announced today that Cyprotex US celebrated the grand opening of its new state-of-the-art facility in Framingham, MA, today. Evotec announced the relocation of Cyprotex US, LLC to the new 30,000 square feet facility at at 200 Staples Drive in Framingham, MA in February. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/cyprotex-us-celebrates-grand-opening-of-new-facility-in-framingham-ma-6283
Evotec-Sernova Partnership: Successful Results Presented at the 4th IPITA/HSCI/JDRF Summit
Evotec’s partner Sernova, a clinical-stage company and leader in cell therapeutics, today announced the presentation of preclinical data supporting the anticipated 2024 IND submission and planned Phase 1/2 clinical trial of Evotec SE’s (FSE: EVT; NASDAQ: EVO) iPSC-derived ILCs in combination with Sernova’s implantable Cell Pouch device for the treatment of patients with T1D. The objective of the partnership is to produce an off-the-shelf, commercially scalable cell therapy treatment, with human testing anticipated to begin in 2024. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-sernova-partnership-successful-results-presented-at-the-4th-ipitahscijdrf-summit-6281
Evotec-Partner Tubulis Announces Strategic License Agreement with Bristol Myers Squibb
Evotec-partner Tubulis and Bristol Myers Squibb (NYSE: BMY) today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates („ADCs“). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-partner-tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-6279
CEO-Letter: #researchneverstops cannot be stopped by cyber-attacks
Dear Friends of Evotec, We detected a cyber-attack on 6 April. I write you today from my temporary E-Mail werner.lanthaler@evotec.eu, which might appear as a sign that we are “back”, but in fact we have never been “gone”. Cyber-attacks are malicious acts, that we all have to accept as a new reality in business life. However, our mission research never stops (#ResearchNeverStops), also not due to cyber-attacks! Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/ceo-letter-researchneverstops-cannot-be-stopped-by-cyber-attacks-6277
Evotec SE provides update on cyber attack
Evotec SE today announced an update on the cyber attack that was detected on 06 April, 2023. Evotec noticed unusual activity in one of the Company’s IT systems and immediately took steps to maintain IT security and remediate the impact. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-provides-update-on-cyber-attack-6276